Sarepta Therapeutics (SRPT) PT Lowered to $200 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Baird 'Incrementally Positive' on Sarepta (SRPT) on Solid Biosciences Clinical Hold
November 12, 2019 11:27 AM ESTBaird analyst Brian Skorney reiterated an Outperform rating and $181.00 price target on Sarepta Therapeutics (NASDAQ: SRPT), saying they are incrementally positive on competitor clinical hold.
Skorney commented, "This morning Solid Biosciences (not covered) announced that the ongoing Phase 1/2 study of SGT-001,... More
